<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241208063991N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-05-16</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of topical insulin on oral lichen planus</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of topical insulin in comparison of placebo in the treatment of patients with oral lichen planus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-04-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>38</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/81258</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: No, Randomization description: Randomization: Random assignment of patients to local normal saline group (A) and local insulin group (B) will be done through block randomization as follows. In this way, each individual will be considered as a block. Binary blocks will be constructed in such a way that the AB combination (A means local normal saline, B means local insulin) will be given to the right of the individual and the local insulin to the left. Similarly, the BA combination will be given to the right of the individual and the local normal saline to the left. To prepare the random list, a random number table will be used in such a way that a random number will be selected at each stage. If the selected number will be between 0 and 4, the AB combination will be considered, and if the selected number will be between 5 and 9, the BA combination will be considered. In addition, in this study, blocks of 4, 6, and 8 will be used randomly to prepare the random list, Blinding description: Both groups are given solutions without explanation of the type of solution, and the code is written as the letter A on the insulin solution and the letter B on the normal saline solution, which can be distinguished by the research team. Assignment to group A or B will be done based on a random table.</study_design>
      <phase>2</phase>
      <hc_freetext>Oral Lichen planus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 19 patients receive topical insulin, 1 cc of regular topical insulin, 2 units per cc, twice daily for 3 months. Patients will be visited monthly and lesion size will be measured in square centimeters and photographs will be taken.                                                                Control group: 19 patients receive topical normal saline. In the second group, topical normal saline will be applied twice daily for 3 months. Patients will be visited monthly and lesion size will be measured in square centimeters and photographs will be taken. Intervention 2: Control group: 19 patients will receive topical normal saline. In this group, topical normal saline will be applied to the lesions twice a day, one cc, for three months. Patients will be visited every month and the size of the lesion will be measured in square centimeters and a photograph will be taken of the patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data for all variables is provided upon request

When:
Data will be available all the time on request

To whom:
Data will be available for academic institution

Conditions:
Data will be provided for other academic institution. Requests should be approved by Tehran University of Medical science

Where to obtain:
Tehran University of Medical Science

How to obtain:
The process of obtaining data involve the research center in tehran university of medical science/ dermatology department.

Comments:
no additional comments</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ashid Mohamed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 64, Khandan alley ,Vahdat-e-eslami street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416753955</zip>
        <telephone>+98 910 752 7437</telephone>
        <email>asheed.almohammadi94@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Asheed Mohamed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 64, Khandan alley ,Vahdat-e-eslami street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1416753955</zip>
        <telephone>+98 910 752 7437</telephone>
        <email>asheed.almohammadi94@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with a confirmed diagnosis of Oral Lichen Planus
From any age group</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diabetic patients
Immunosuppressive patients
Pregnant ladies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L43.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lichen planus, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 19 patients receive topical insulin, 1 cc of regular topical insulin, 2 units per cc, twice daily for 3 months. Patients will be visited monthly and lesion size will be measured in square centimeters and photographs will be taken.                                                                Control group: 19 patients receive topical normal saline. In the second group, topical normal saline will be applied twice daily for 3 months. Patients will be visited monthly and lesion size will be measured in square centimeters and photographs will be taken.</i_keyword>
      <i_keyword>Control group: 19 patients will receive topical normal saline. In this group, topical normal saline will be applied to the lesions twice a day, one cc, for three months. Patients will be visited every month and the size of the lesion will be measured in square centimeters and a photograph will be taken of the patient.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The size of oral lichen planus lesions. Timepoint: Measurement of oral lichen planus lesion size will be performed at the beginning of the study (before the intervention begins) and 1, 2, and 3 months later. Method of measurement: The size of the waste will be measured with a ruler (unit: centimeters).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-11-13</approval_date>
        <contact_name>Ethics Committe of College of Medicine, Tehran University of Medical Science</contact_name>
        <contact_address>Razi Hospital, Vahdat-e- eslami streat, Shapour square, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
